Researchers Decode Molecular Action of Combination Therapy for a Deadly Thyroid Cancer

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic Cancer Center's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal. In testing multiple HDAC inhibitors in combination with the chemotherapy drug paclitaxel, known to give some benefit for this aggressive cancer, they found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemoth...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news